‘Takeda remains confident. In the safety and efficacy of pioglitazone, when used according to the label, and with this revision, we can improve patient and physician awareness of an already known, but serious side effect ‘.. Takeda Pharmaceuticals North America,Takeda Pharmaceuticals North America, today announced that the company has to work now warning congestive heart failure in the prescribing label of the type 2 diabetes drug Actos . Takeda operates in conjunction with a request from the U.S.
An increase in mortality or in total macrovascular events, including heart attacks and strokes. PROactive showed that pioglitazone, in addition to standard of care has a proven safety profile in patients with type 2 diabetes at high risk at high risk for cardiovascular events.. ACTOS Cardiovascular Safety DataThe ACTOS label was last updated in February 2007 to incorporate important cardiovascular safety data from the PROactive study , a large outcome study. The updated ACTOS label confirmed 2 diabetes.vascular events.About the Author: James Hampshire are based from the School of Social Sciences and Cultural Studies, University of Sussex. He researched and taught immigration policies and policy on several years. This year publishing a book about immigration policies in post-war UK and currently works a project on of immigration and liberal democracy.